Polyposis syndromes are a group of inherited conditions that cause dozens to thousands of growths, called polyps, to develop along the lining of the digestive tract. These polyps carry a significant risk of becoming cancerous, sometimes approaching 100% over a lifetime if left untreated. Several distinct syndromes fall under this umbrella, each linked to a different gene mutation, but they share a common thread: the need for early detection and lifelong surveillance.
The Major Types of Polyposis Syndromes
Polyposis syndromes are classified by the type of polyp they produce and the gene responsible. The most well-known include:
- Familial adenomatous polyposis (FAP), caused by mutations in the APC gene, produces hundreds to thousands of precancerous adenomatous polyps throughout the colon and rectum.
- MUTYH-associated polyposis (MAP), caused by mutations in the MUTYH gene, typically produces ten to a few hundred adenomatous polyps in the colon.
- Peutz-Jeghers syndrome (PJS), caused by mutations in the STK11 gene, produces a different kind of polyp called a hamartomatous polyp, most commonly in the small intestine.
- Juvenile polyposis syndrome (JPS), diagnosed when someone has more than five juvenile polyps in the colon or rectum, or polyps throughout the digestive tract alongside a family history of the condition.
FAP and Peutz-Jeghers syndrome follow a dominant inheritance pattern, meaning a child needs to inherit only one copy of the mutated gene from one parent to develop the condition. MAP is different. It follows a recessive pattern, so a person needs to inherit a defective copy from both parents. Each sibling of someone with MAP has a 25% chance of being affected.
Familial Adenomatous Polyposis (FAP)
FAP is the most common and most aggressive polyposis syndrome. Polyps begin appearing at an average age of 16, far earlier than the sporadic polyps most people develop later in life. Without treatment, the lifetime risk of colorectal cancer approaches 100%. That near-certainty is why FAP typically leads to preventive surgery rather than ongoing polyp removal alone.
FAP doesn’t stop at the colon. People with this syndrome face a 4.5% to 10% cumulative risk of duodenal cancer (cancer of the upper small intestine) by age 57 to 60, which is 100 to 330 times higher than the general population. Thyroid cancer is the third most common malignancy in FAP, with a lifetime risk of about 2%.
A variant called Gardner syndrome involves the same APC gene mutation but adds features outside the digestive tract: bony growths (osteomas) on the jaw and skull, extra or unusually rooted teeth, and soft-tissue tumors like desmoid tumors that grow in the abdomen. Dental abnormalities can appear in childhood, sometimes before polyps are even detected, making dentists an unexpected first line of recognition. Osteomas show up in 26% to 46% of Gardner syndrome patients, and abnormalities in the pigmented layer of the eye occur in roughly 90% of cases.
MUTYH-Associated Polyposis (MAP)
MAP tends to be milder in polyp count than FAP, with most affected people developing between ten and a few hundred colon polyps. The average age at presentation is around 50, decades later than FAP. But a lower polyp count doesn’t mean lower vigilance is appropriate. Colorectal cancer can develop in some individuals with MAP even without visible polyposis, and the syndrome also raises the risk of cancers in the duodenum, stomach, ovary, and bladder.
The polyps in MAP aren’t limited to one type. They can include adenomatous polyps, serrated polyps, and hyperplastic polyps, which sometimes complicates diagnosis. Genetic testing for MUTYH mutations is the definitive way to confirm MAP, particularly in people under 60 who have a cumulative history of ten or more colorectal polyps.
Peutz-Jeghers Syndrome
Peutz-Jeghers syndrome has a visible calling card that often appears before any digestive symptoms: dark blue to dark brown freckle-like spots around the mouth, eyes, nostrils, fingertips, toes, and perianal area. These spots typically show up in childhood. In one series, 94% of people with PJS had perianal pigmentation, 73% had spots on their fingers, and 65% had spots inside the cheek.
The polyps in PJS are hamartomatous, meaning they contain an overgrowth of normal tissue rather than the precancerous cells seen in adenomatous polyps. They occur most densely in the jejunum (the middle section of the small intestine), followed by the ileum and duodenum, though they can also appear in the stomach and large bowel. These polyps can grow large enough to cause blockages or bleeding, sometimes requiring emergency treatment in children and young adults.
Despite being non-adenomatous, PJS carries a broad cancer risk. People with the syndrome face elevated lifetime risks for cancers of the breast, colon, pancreas, ovary, stomach, lung, and small intestine.
Juvenile Polyposis Syndrome
JPS is diagnosed when someone has more than five juvenile polyps in the colon or rectum, juvenile polyps scattered throughout both the upper and lower digestive tract, or any number of juvenile polyps combined with a family history of the condition. “Juvenile” refers to the polyp type, not the patient’s age, though symptoms often begin in childhood with rectal bleeding or anemia.
The cancer risks in JPS extend beyond the colon. Gastric cancer occurs in roughly 13.7% of affected individuals, with duodenal and pancreatic cancers each reported at about 3.4%.
Screening Timelines for Carriers
Because polyposis syndromes are inherited, genetic testing can identify carriers before polyps ever develop. Screening recommendations differ significantly depending on the syndrome.
For FAP, colonoscopy should begin between ages 10 and 15 and repeat every year. This early start reflects how quickly polyps accumulate during the teenage years. For MAP, colonoscopy is recommended every one to two years starting between ages 25 and 30, with the exact interval depending on polyp burden. If polyps are few and manageable, the interval can stretch to every three years in some cases.
Surveillance isn’t limited to the colon. Because FAP and other syndromes raise the risk of cancers in the upper digestive tract, thyroid, and other organs, screening programs typically include upper endoscopy and, for FAP, thyroid examinations.
When Surgery Becomes Necessary
For many people with polyposis syndromes, preventive surgery to remove the colon is not a question of “if” but “when.” In FAP, absolute triggers for surgery include confirmed or suspected cancer, severe symptoms from the polyp burden, 1,000 or more polyps at colonoscopy, or biopsy results showing high-grade precancerous changes. Planned surgery is recommended when polyps exceed 10 millimeters in diameter, polyp numbers increase substantially between exams, or the total polyp count falls between 100 and 1,000.
The type of surgery depends on how severely the rectum is affected. When there are 20 or more rectal polyps or roughly 500 or more colon polyps, the entire colon and rectum are typically removed and an internal pouch is constructed to preserve bowel function. When rectal involvement is mild, the rectum can sometimes be preserved, though it will need lifelong monitoring for new polyps.
For MAP and other lower-burden syndromes, surgery may be avoidable if polyps can be managed through regular endoscopic removal. The decision depends on how many polyps are present, how fast new ones grow, and whether any show precancerous features.
Living With a Polyposis Syndrome
A polyposis diagnosis reshapes the medical calendar for the rest of your life. Annual or biannual colonoscopies become routine. Family members need genetic testing, since each syndrome follows a predictable inheritance pattern and early identification in relatives can be lifesaving. Children of someone with FAP or PJS have a 50% chance of inheriting the mutation, while siblings of someone with MAP have a 25% chance.
The emotional weight of managing a condition with near-certain cancer risk is real, but the outlook has improved dramatically with modern surveillance. When polyps are caught early and managed aggressively, whether through endoscopic removal or preventive surgery, the cancers these syndromes are known for can often be prevented entirely.